【摘要】 目的 评价赛美维（ｇａｎｃｉｃｌｏｖｉｒ） 在异基因骨髓移植（ａｌｌｏＢＭＴ） 合并巨细胞病毒（ＣＭＶ） 感染中应用的有效性及安全性。方法 观察ａｌｌｏＢＭＴ 合并ＣＭＶ 患者６０ 例，其中预防组４０ 例，治疗组２０ 例。赛美维预防方案为：静滴５ ｍｇ／ｋｇ ，每１２ 小时１ 次，－ ９～－ ２ 天。ａｌｌｏＢＭＴ 后自中性粒细胞≥１．０×１０９／Ｌ及ＢＰＣ≥３０×１０９／Ｌ开始用药，剂量５ ｍｇ ·ｋｇ － １ ·ｄ－ １ ，每周用药５ 天，直至＋ １００ 天。治疗方案为：静滴５ ｍｇ／ｋｇ ，每１２ 小时１ 次，２～３ 周，之后按原剂量每周用药５ 天，再持续２～３ 周。结果 预防性应用赛美维２０ 例均未发生活动性ＣＭＶ 感染，而未用赛美维预防对照组２０ 例中即有５ 例发生活动性ＣＭＶ 感染（ Ｐ＜ ０．０５） 。用赛美维预防治疗组２０ 例中显效１７ 例（占８５％ ）。赛美维的主要不良反应为白细胞及血小板减少，但均为可逆性。结论 赛美维对于ａｌｌｏＢＭＴ 合并ＣＭＶ 感染的预防与治疗的疗效可靠、用药安全，可作为一线用药。更多还原

【Abstract】 Objective To assess the efficacy and safety of Cymevene (ganciclovir) in the prophylaxis and treatment of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation (allo BMT). Methods Sixty patients with leukemia undergoing allo BMT were observed. Cymevene was given prophylactically to 20 patients at a dose of 5 mg/kg twice daily from day -9 to day -2 and restarted when the ANC≥1.0×109/L and BPC≥30×109/L at a daily dose of 5 mg/kg for 5 days every week until day +100. In diagnosed symptomatic CMV infections, the dose of Cymevene was 5mg/kg twice daily for 2～3 weeks followed by 5 mg/kg twice a day for 5 days every week for an additional 2～3 weeks. Results The incidence of active CMV infection was 0 in the prophylaxis treated patients and 25%in the controls (P<0.05). In diagnosed CMV diseases, marked improvement was noted in 17 of 20 patients (85%) treated with Cymevene. The most common adverse events of Cymevene were leukopenia and thrombocytopenia, but were reversible. Conclusion Cymevene is effective and safe for the prophylaxis and treatment of CMV infections after allo BMT.更多还原